Skip to content
    Real-World Studies

    Real-World Efficacy and Safety of Fosaprepitant Quadruple Prophylaxis in Chemotherapy

    Celayir et alMedical Bulletin of Sisli Etfal Hospital

    A two-center retrospective study evaluated the real-world clinical efficacy and safety of a fosaprepitant-based quadruple antiemetic regimen in 50 adult oncology patients receiving highly emetogenic chemotherapy (HEC; 82%) or moderately emetogenic chemotherapy (MEC; 18%). The antiemetic protocol combined fosaprepitant, dexamethasone, granisetron, and olanzapine. The primary endpoint was complete response (defined as no emetic episodes within 0–120 hours post-chemotherapy). The patient cohort was predominantly female (80%) and younger than 65 years (84%), with breast cancer (38%) and pancreatic-biliary malignancies (18%) being the most common primary diagnoses.
    Overall, complete vomiting control within 0–120 hours was attained in 80% of treated patients, whereas 48% remained entirely free of nausea. Subgroup analysis showed complete response rates of 85.4% in the HEC group versus 55.6% in the MEC group, though the difference did not achieve statistical significance (p=0.118). Similarly, patients with clinically significant anxiety based on the Beck Anxiety Inventory exhibited lower complete response rates than those with low anxiety (66.7% vs 82.4%), but this trend was also non-significant (p=0.475). Other clinical factors—including alcohol consumption, prior hyperemesis gravidarum (22%), and history of motion sickness (18%)—demonstrated no significant correlation with treatment outcomes (all p>0.05). Despite high rates of emesis prevention, 52% of patients required rescue antiemetics. The regimen was well tolerated overall, with fatigue (10%) and dyspepsia (4%) reported as the most frequent adverse events.

    Key Takeaways

    • A quadruple antiemetic regimen of fosaprepitant, dexamethasone, granisetron, and olanzapine achieved an overall complete response rate (no vomiting within 0–120 hours) of 80%, with 48% of patients reporting complete absence of nausea.
    • Complete response rates were 85.4% in patients receiving highly emetogenic chemotherapy compared to 55.6% in those receiving moderately emetogenic chemotherapy (p=0.118), with no statistically significant response differences associated with anxiety level, alcohol history, hyperemesis gravidarum, or motion sickness.
    • Rescue antiemetics were needed in 52% of patients, while treatment-related adverse events were infrequent, predominantly comprising fatigue (10%) and dyspepsia (4%).
    Read the original sourceMedical Bulletin of Sisli Etfal Hospital